Literature DB >> 9016527

Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects.

P Hainaut1, T Soussi, B Shomer, M Hollstein, M Greenblatt, E Hovig, C C Harris, R Montesano.   

Abstract

In recent years, there has been an exponential increase in the number of p53 mutations identified in human cancers. The p53 mutation database consists of a list of point mutations in thep53 gene of human tumors and cell lines, compiled from the published literature and made available through electronic media. The database is now maintained at the International Agency for Research on Cancer (IARC) and is updated twice a year. The current version contains records on 5091 published mutations and is expected to surpass the 6000 mark in the January 1997 release. The database is available in various formats through the European Bioinformatics Institute (EBI) ftp server at: ftp://ftp.ebi.ac.uk/pub/databases/p53/ or by request from IARC (p53database@iarc.fr) and will be searchable through the SRS system in the near future. This report provides a description of the criteria for inclusion of data and of the current formats, a summary of the relevance ofp53 mutation analysis to clinical and biological questions, and a brief discussion of the prospects for future developments.

Entities:  

Mesh:

Year:  1997        PMID: 9016527      PMCID: PMC146396          DOI: 10.1093/nar/25.1.151

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  27 in total

1.  SRS--an indexing and retrieval tool for flat file data libraries.

Authors:  T Etzold; P Argos
Journal:  Comput Appl Biosci       Date:  1993-02

2.  Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes.

Authors:  F Aguilar; S P Hussain; P Cerutti
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

3.  p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis.

Authors:  S Saitoh; J Cunningham; E M De Vries; R M McGovern; J J Schroeder; A Hartmann; H Blaszyk; L E Wold; D Schaid; S S Sommer
Journal:  Oncogene       Date:  1994-10       Impact factor: 9.867

4.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

Authors:  Y Cho; S Gorina; P D Jeffrey; N P Pavletich
Journal:  Science       Date:  1994-07-15       Impact factor: 47.728

5.  Pattern of p53 gene mutations in breast cancers of women of the midwestern United States.

Authors:  S S Sommer; J Cunningham; R M McGovern; S Saitoh; J J Schroeder; L E Wold; J S Kovach
Journal:  J Natl Cancer Inst       Date:  1992-02-19       Impact factor: 13.506

Review 6.  Does a genotoxic carcinogen contribute to human breast cancer? The value of mutational spectra in unravelling the aetiology of cancer.

Authors:  P J Biggs; W Warren; S Venitt; M R Stratton
Journal:  Mutagenesis       Date:  1993-07       Impact factor: 3.000

Review 7.  The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer.

Authors:  T Soussi
Journal:  Mol Med Today       Date:  1996-01

Review 8.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

9.  p53 mutation hotspot in radon-associated lung cancer.

Authors:  J A Taylor; M A Watson; T R Devereux; R Y Michels; G Saccomanno; M Anderson
Journal:  Lancet       Date:  1994-01-08       Impact factor: 79.321

10.  Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation.

Authors:  K Ory; Y Legros; C Auguin; T Soussi
Journal:  EMBO J       Date:  1994-08-01       Impact factor: 11.598

View more
  73 in total

Review 1.  Soft tissue sarcomas and p53 mutations.

Authors:  H Taubert; A Meye; P Würl
Journal:  Mol Med       Date:  1998-06       Impact factor: 6.354

2.  Functional analysis of the p53 codon 72 polymorphism in black South Africans with rheumatoid arthritis--a pilot study.

Authors:  Devapregasan Moodley; Girish M Mody; Anil A Chuturgoon
Journal:  Clin Rheumatol       Date:  2010-06-10       Impact factor: 2.980

3.  Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis.

Authors:  C M Eischen; D Woo; M F Roussel; J L Cleveland
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

4.  Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras.

Authors:  Sergio Acin; Zhongyou Li; Olga Mejia; Dennis R Roop; Adel K El-Naggar; Carlos Caulin
Journal:  J Pathol       Date:  2011-09-26       Impact factor: 7.996

5.  Analysis of p21Waf1/Cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma.

Authors:  H Hayashi; H Miyamoto; T Ito; Y Kameda; N Nakamura; Y Kubota; H Kitamura
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

6.  Hzf, a p53-responsive gene, regulates maintenance of the G2 phase checkpoint induced by DNA damage.

Authors:  Masataka Sugimoto; Adam Gromley; Charles J Sherr
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

7.  Mismatch-induced DNA unbending upon duplex opening.

Authors:  Chongli Yuan; Elizabeth Rhoades; Daniel M Heuer; Lynden A Archer
Journal:  Biophys J       Date:  2005-08-05       Impact factor: 4.033

8.  Dissecting the contribution of p16(INK4A) and the Rb family to the Ras transformed phenotype.

Authors:  Philip J Mitchell; Elena Perez-Nadales; Denise S Malcolm; Alison C Lloyd
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

9.  The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.

Authors:  F J Stott; S Bates; M C James; B B McConnell; M Starborg; S Brookes; I Palmero; K Ryan; E Hara; K H Vousden; G Peters
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

10.  Effects of mutant human Ki-ras(G12C) gene dosage on murine lung tumorigenesis and signaling to its downstream effectors.

Authors:  Stephanie T Dance-Barnes; Nancy D Kock; Heather S Floyd; Joseph E Moore; Libyadda J Mosley; Ralph B D'Agostino; Mark J Pettenati; Mark Steven Miller
Journal:  Toxicol Appl Pharmacol       Date:  2008-04-27       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.